About Structure Therapeutics Inc.
https://structuretx.comStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs.
CEO
Raymond C. Stevens
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 25
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
WELLINGTON MANAGEMENT GROUP LLP
Shares:5.69M
Value:$479.77M
FMR LLC
Shares:5.25M
Value:$442.76M
AVORO CAPITAL ADVISORS LLC
Shares:5.16M
Value:$434.77M
Summary
Showing Top 3 of 168
About Structure Therapeutics Inc.
https://structuretx.comStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $73.79M ▲ | $-65.71M ▼ | 0% | $-1.11 ▼ | $-65.31M ▲ |
| Q2-2025 | $0 | $70.45M ▲ | $-61.66M ▼ | 0% | $-1.08 ▼ | $-70.16M ▼ |
| Q1-2025 | $0 | $56.31M ▲ | $-46.83M ▼ | 0% | $-0.81 ▼ | $-56.04M ▼ |
| Q4-2024 | $0 | $47.06M ▲ | $-36.48M ▼ | 0% | $-0.63 ▼ | $-46.79M ▼ |
| Q3-2024 | $0 | $45.84M | $-33.98M | 0% | $-0.6 | $-45.57M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $799.04M ▲ | $832.16M ▲ | $62.14M ▲ | $770.02M ▼ |
| Q2-2025 | $786.5M ▼ | $816.44M ▼ | $44.36M ▲ | $772.08M ▼ |
| Q1-2025 | $836.88M ▼ | $866.55M ▼ | $41.91M ▲ | $824.64M ▼ |
| Q4-2024 | $883.52M ▼ | $903.33M ▼ | $38.49M ▲ | $864.84M ▼ |
| Q3-2024 | $915.29M | $933.22M | $36.42M | $896.8M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-65.71M ▼ | $-51M ▲ | $-49.32M ▼ | $56.2M ▲ | $-44.11M ▼ | $-52.57M ▲ |
| Q2-2025 | $-61.66M ▼ | $-54.56M ▼ | $48.94M ▲ | $517K ▼ | $-5.1M ▲ | $-54.79M ▼ |
| Q1-2025 | $-46.83M ▼ | $-52.23M ▼ | $34.03M ▲ | $809K ▲ | $-17.39M ▼ | $-52.54M ▼ |
| Q4-2024 | $-36.48M ▼ | $-36.47M ▼ | $33.23M ▲ | $615K ▲ | $-2.62M ▲ | $-36.48M ▼ |
| Q3-2024 | $-33.98M | $-19.7M | $-189.04M | $-757K | $-209.5M | $-20.38M |
CEO
Raymond C. Stevens
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 25
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
WELLINGTON MANAGEMENT GROUP LLP
Shares:5.69M
Value:$479.77M
FMR LLC
Shares:5.25M
Value:$442.76M
AVORO CAPITAL ADVISORS LLC
Shares:5.16M
Value:$434.77M
Summary
Showing Top 3 of 168